Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Have moderate to severe active UC as defined by a Mayo score of 6 to 12 with an endoscopic subscore ≥2 within 14 days before the first dose of study treatment (note: a partial Mayo score of at least 4 and other eligibility criteria must have been met before endoscopy is performed as a study procedure)~* Have evidence of UC extending proximal to the rectum (≥15 centimeters \[cm\] of involved colon)~* Up-to-date colorectal cancer surveillance (performed according to local standard), for subjects with family history of colorectal cancer, personal history of increased colorectal cancer risk, age \>50 years, or other known risk factor~* Participants must either: be naive to biologic therapy (eg, tumor necrosis factor \[TNF\] antagonists or vedolizumab) and have at least 1 of the following: inadequate response or failure to tolerate current treatment with oral or intravenous corticosteroids or immunomodulators (6-mercaptopurine or azathioprine) or history of corticosteroid dependence (an inability to successfully taper corticosteroids without return of UC) OR have received treatment with 1 or more biologic agents (eg, TNF antagonists or vedolizumab) at doses approved for the treatment of UC with documented history of failure to respond to or tolerate such treatment~Exclusion Criteria:~* Have been diagnosed with indeterminate colitis, proctitis (distal disease involving the rectum only; less than 15 cm from the anal verge) or Crohn's Disease~* Have had surgery for treatment of UC or are likely to require surgery for UC during the study~* Have received any of the following for treatment of UC: cyclosporine or thalidomide within 30 days of screening, corticosteroid enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 50 mg Mirikizumab IV Q4W (Induction) (Type: EXPERIMENTAL): 50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
- 200 mg Mirikizumab IV Q4W (induction) (Type: EXPERIMENTAL): 200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
- 600 mg Mirikizumab IV Q4W (Induction) (Type: EXPERIMENTAL): 600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
- Placebo IV Q4W (Induction) (Type: PLACEBO_COMPARATOR): Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
- 200 mg Mirikizumab SC Q4W (Maintenance) (Type: EXPERIMENTAL): Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
- 200 mg Mirikizumab SC Q12W (Maintenance) (Type: EXPERIMENTAL): Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
- Placebo SC Q4W (Maintenance) (Type: PLACEBO_COMPARATOR): Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
- 600mg Mirikizumab IV Q4W Extension Open-Label (Type: EXPERIMENTAL): Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
- 1000mg Mirikizumab IV Q4W Extension Open-Label (Type: EXPERIMENTAL): Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
- 200mg Mirikizumab SC Q4W Extension Open-Label (Type: EXPERIMENTAL): Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete